SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Isotechnika
An SI Board Since August 2001
Posts SubjectMarks Bans Symbol
285 8 0 ISA
Emcee:  schzammm Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
235Thanks. I have a smallish position that I'm holding long term. Almost never fred hayes-2/20/2006
234fred, I would be careful. There were a few large block trades before the new anateevee-2/19/2006
233Cool. thanks for posting that... eomfred hayes-2/16/2006
232USD $6 price target?? We are initiating coverage of Isotechnika, Inc. with a Buteevee-2/16/2006
23115-Feb-2006 WR Hambrecht + Co. Andrew Forman ISA.TO: IMPROVING IMMUNOSUPPRESSANTteevee-2/16/2006
230Isotechnika receives additional U.S. patent for lead immunosuppressive drug, ISAnigel bates-2/14/2006
229For those of you interested in the renal trial details. clinicaltrials.govteevee-2/8/2006
228The Business Journal January 13, 2006 For the past few years, Koziak has run theteevee-1/19/2006
227Isotechnika enrols first patient in Phase IIb kidney transplant trial Thursday Jnigel bates-1/5/2006
226Isotechnika appoints Mary Ritchie to its Board of Directors Wednesday January 4,nigel bates-1/4/2006
225Is this just the tip of the iceberg? There have been a number of recent resignatteevee-12/20/2005
224The previous article was posted on the Stockhouse ISA board today but it disappeDaveAu-12/20/2005
223bloomberg.com David Evans is a reporter for Bloomberg News in Los Angeles. The DaveAu-12/20/2005
222Isotechnika's Phase III psoriasis spirit trial achieves safety and efficacy nigel bates-11/7/2005
221Isotechnika to announce Phase III psoriasis spirit trial results EDMONTON, NovJohn McCarthy-11/6/2005
220ISA To Present at BIO InvestorForum 2005 Showcasing the Leading Growth Companieteevee-10/17/2005
219I threw in the towel on this one several weeks ago. Best to all who remian in ISschzammm-10/8/2005
218Isotechnika Reappoints Transplant Surgeon as Medical Affairs Director Friday Octteevee-10/7/2005
217Isotechnika and Atrium Medical announce licensing agreement for use of TAFA93 anteevee-10/2/2005
216Caution may be warranted in evaluating these results: Message 21723488DewDiligence_on_SI-9/21/2005
215Here are kidney function numbers for CYA by comparison: <i> Clin Nephrol.Biomaven-9/21/2005
214Isotechnika's Phase III psoriasis trial achieves clinical endpoints Wednesdanigel bates-9/21/2005
213Press Release Source: Isotechnika Inc. Isotechnika announces ninety percent pateevee-9/14/2005
212Isotechnika completes financing for total proceeds of $20,025,000 EDMONTON, Julteevee-7/12/2005
211Thank you. CCondor-6/23/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News